Introduction 48 49
Clostridium difficile is the leading infective cause of antibiotic-associated diarrhoea and a major 50 public health concern. Treatment options for C. difficile infection (CDI) are limited. Guidelines 51 published by PHE 1 list extended vancomycin as an option for patients with multiple recurrences, 52 however, no specific regimen is recommended. Tedesco Two gut models were set up and run in parallel, as previously described.
8 Models were inoculated 75 with a 10% faecal emulsion prepared from C. difficile-negative faeces of three healthy volunteers 76 years) with no history of antimicrobial therapy for 3 months. were inoculated into vessel 1. Seven days later a second inoculum of spores (~10 7 cfu), were added 82 to vessel 1 alongside clindamycin (33.9 mg/L, four-times daily, 7 days period C). After C. difficile 83 germination, proliferation and toxin detection (3 relative units), vancomycin instillation commenced 84
(Period E). Initially the vancomycin dosing regimens of the two models were the same (125 mg/L, 85 four-times daily, 7 days). Subsequent dosing is outlined in Figure 1 . Following treatment, models 86 were observed for a further 21 days with no interventions. 87
88
Enumeration of gut microbiota and C. difficile and quantification of toxin and antimicrobialIndigenous gut microbiota (periods A-F, vessels 2&3), C. difficile total viable counts (TVC) and spores 90 (periods A-F, all vessels), cytotoxin (periods B-F, all vessels), and antimicrobial concentrations 91 (periods C-F, all vessels) were monitored daily as previously described in detail. In both models C.difficile spores remained quiescent during period B, and were gradually diluted out 120 of the model. Following clindamycin instillation C. difficile total viable counts (TVC) increased 121 relative to spore counts, peaking at ~6 log 10 cfu/mL , and cytotoxin (3 RU) was detected (Figure 2a , 122 2b). In both models, vancomycin instillation (period E) resulted in a rapid decline in C. difficilevegetative populations and toxin levels. In the lower-dosage model C.difficile spores were only 124 sporadically detected at around the limit of detection for the remainder of the experiment. 125
However in the higher-dosage model an increase in C. difficile TVCs relative to spores (recurrence of 126 simulated CDI) was observed on the final 2 days of the experiment (days 119-120), peaking at 5.0 127 log 10 cfu/mL in vessel 3, although toxin remained undetectable ( figure 2a) . 128
129

Effect of treatment regimens on indigenous gut microbiota and vancomycin tolerant Enterococci 130
In both models, gut microbiota populations reached steady state by the end of period A and 131 remained relatively stable throughout period B. Clindamycin instillation (period C) elicited 132 disruptions similar to those previously reported. 9, 11 Vancomycin instillation resulted in a precipitous 133 decline in B. fragilis group populations in both models ( figure 2c, 2d) . These recovered to pre-134 vancomycin levels ~ 1 week before the end of the vancomycin dosing in the lower-dosage model, 135
but not until 5 days post treatment (period F) in the higher-dosage model. Bifidobacterium spp. 136 declined to below the limit of detection (LOD) (~1.2 log 10 cfu/mL) in both models and were not 137 detected for the remainder of the experiment. 138
139
Prior to vancomycin instillation, VTE were sporadically detected at ~2-3 log 10 cfu/mL in both models 140 (at least ~2 log 10 cfu/mL lower than total enterococci populations). However, the proportion of VTEs 141 increased during vancomycin exposure. In both models, total enterococci populations were largely 142 equal to VTE populations (~4-6 log 10 cfu/mL) following the end of vancomycin dosing (Figure 2e, 2f) . 12-14 Such regimens have been extensively evaluated in the gut model, and whilst they lead 148 to rapid initial clinical cure, recurrent vegetative cell proliferation and toxin production is frequently 149 observed. 4-6, 15, 16 The vancomycin extended-dosing regimens evaluated here also led to a rapid 150 decrease in vegetative C. difficile populations and toxin initially, and inhibited growth during 151 instillation. However, in the higher-dosage model, recurrence of C. difficile germination and 152 proliferation was observed on the penultimate day of the experiment. intestinal microbiota dysbiosis in a dose-dependant manner, and may select for vancomycin 186 resistance. Therefore, other treatment strategies to treat recurrent CDI should be considered; 187 therapeutic options that are less prone to cause microbiota dysbiosis may be preferable considering 188 that CDI usually develops in the setting of antibiotic-mediated microflora disturbance. 189 populations (log 10 cfu/mL) in vessel 3 of (c) the lower dosage and (d) the higher dosage model 278 (Clostridium spp. limit of detection = 5.22 log 10 cfu/mL, limit of detection other microbiota = 1.2 279 log 10 cfu/mL). (e, f) Total Enterococcus spp. and vancomycin tolerant enterococci (VTE) populations in 280 vessel 3 of (e) the lower dosage and (f) the higher dosage models. 281 282 283
